Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen shares have fallen almost 5% after Boehringer Ingelheim discontinued development of bivatuzumab mertansine as the treatment candidate failed a phase I trial.
Subscribe to our email newsletter
Bivatuzumab mertansine consists of the Boehringer Ingelheim anti-CD44v6 antibody, bivatuzumab, and ImmunoGen’s DM1 cytotoxic agent, mertansine. Development of bivatuzumab mertansine was discontinued due to the occurrence of skin toxicity in phase I clinical trials in patients with advanced carcinoma.
Although Boehringer Ingelheim has decided to discontinue this program, the company is retaining its right to use ImmunoGen technology for a different oncology target.
CD44v6 is expressed on various carcinomas, including squamous cell carcinomas and a proportion of adenocarcinomas. Published data indicate that the CD44v6 antigen is also expressed on normal proliferating epidermal cells.
In 2001, Boehringer Ingelheim licensed the right to use ImmunoGen’s DM1 tumor-activated prodrug (TAP) technology. Under this agreement, Boehringer Ingelheim can use ImmunoGen’s DM1 to create an anticancer compound to a different antigen target in the event of choosing to discontinue development of an anti-CD44v6 TAP compound at an early stage.
“While we are disappointed that bivatuzumab mertansine will no longer be developed, we recognize that only a fraction of the potential new therapeutics that begin clinical testing ever make it to market,” said Dr Mitchel Sayare, ImmunoGen’s chairman and CEO.